Meriwether Wealth & Planning’s Xenon Pharmaceuticals XENE Stock Holding History

Meriwether Wealth & Planning’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.23K	Buy	+33	New	+$1.96K	﹤0.01%	704

Other funds holding XENE

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

J. Safra Sarasin Holding $7.05B AUM 26.14% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Meriwether Wealth & Planning's XENE Position: Q3 2026 in Review

Meriwether Wealth & Planning opened a new position in Xenon Pharmaceuticals (XENE) in Q3 2026: 33 shares worth $1.23K. The stake represents ﹤0.01% of the portfolio and ranks #704 among its holdings.

38 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

Meriwether Wealth & Planning held 33 shares of Xenon Pharmaceuticals worth $1.23K as of Q3 2026.
Xenon Pharmaceuticals was a new Meriwether Wealth & Planning position in Q3 2026.
Xenon Pharmaceuticals made up ﹤0.01% of Meriwether Wealth & Planning's portfolio in Q3 2026, its #704 holding.
38 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Meriwether Wealth & Planning's 13F filing for Q3 2026, filed 13 Oct 2026.